All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

The OncFive: Top Oncology Articles for the Week of 11/24

November 30th 2024

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Targeted Therapies Remain Central to Ongoing Research in Pancreatic Cancer

November 30th 2024

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

USC Study Explores New Insights into Innate Eesistance for Immunotherapies in Colorectal Cancer

November 29th 2024

Researchers find evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases.

Osimertinib Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines and Durvalumab Shakes up SCLC

November 29th 2024

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Obe-Cel Approval Expands CAR T-Cell Therapy Options in Relapsed/Refractory ALL

November 29th 2024

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer

November 28th 2024

A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.

Targeting IL-12 Safely With Intraperitoneal Therapy Represents Key Step Forward in Ovarian Cancer

November 28th 2024

Premal Thaker, MD, MS, discusses considerations when targeting IL-12 in ovarian cancer and how IMNN-001 has shown the potential to do so.

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC

November 27th 2024

ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.

Pancreatic Cancer Awareness Month Brings Attention to Growing Incidence and Treatment Advances

November 27th 2024

Suneel Kamath, MD, took to the OncLive X (Twitter) account during Pancreatic Cancer Awareness Month to share the importance of recognizing this disease.

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

November 27th 2024

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

EC Approves Frontline Tislelizumab Plus Chemo for Advanced ESCC and Gastric/GEJ Cancer

November 27th 2024

Tislelizumab plus chemotherapy has been approved in Europe for first-line advanced ESCC and gastric/GEJ adenocarcinoma.

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

November 27th 2024

Adjuvant ribociclib plus endocrine therapy was approved in Europe for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Sacituzumab Tirumotecan Earns Approval in China in Pretreated Advanced TNBC

November 27th 2024

China’s NMPA has approved sacituzumab tirumotecan for pretreated unresectable locally advanced or metastatic triple-negative breast cancer.

Dr Schlechter Named Cancer Moonshot Scholar

November 27th 2024

Chelsey Schlechter, MPH, PhD, Huntsman Cancer Institute investigator and assistant professor in the Department of Population Health Sciences at the University of Utah, has been selected as a 2024 Cancer Moonshot Scholar.

Discussions Swirl on the Role of PD-1 Inhibitors for Gastric/GEJ/ESCC Cancers With 1%-10% PD-L1 Expression

November 27th 2024

Nataliya Uboha, MD, PhD, and Robert Albert Anders, MD, PhD, unpack the unfavorable risk-benefit profile of PD-1 inhibitors in patients with certain PD-L1–negative gastrointestinal cancers and discussions from a recent ODAC meeting.

Abequolixron/Docetaxel Produces Durable Responses in Recurrent Advanced NSCLC

November 27th 2024

Abequolixron plus docetaxel generated preliminary efficacy signals in the second- and third-line settings in recurrent advanced nonsquamous NSCLC.

MAXILUS Study Looks to Further Elucidate the Role of Luspatercept in MDS

November 26th 2024

The MAXILUS study will evaluate the maximum approved dose of luspatercept in lower-risk myelodysplastic syndrome.

Novel PI3Kα Inhibitor STX-478 Offers Precise Treatment and Reduced Toxicity for Solid Tumors

November 26th 2024

Alberto Montero, MD, MBA, discusses the importance of PI3Kα pathway inhibition in solid tumors and expands on the unique mechanism of action of STX-478.

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

November 26th 2024

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Fox Chase Cancer Center’s Dr. Richard J. Bleicher Appointed Vice Chair of the National Accreditation Program for Breast Centers and Chair of its Executive Committee

November 26th 2024

Richard J. Bleicher, MD, FACS, Chief of the Division of Breast Surgery and Clinical Director of the Breast Service Line at Fox Chase Cancer Center.